Navigation Links
ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia

SEATTLE, June 04, 2007 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. today announced that interim findings were presented from a Phase 1b clinical trial with atacicept in B-cell chronic lymphocytic leukemia (B-CLL) at the American Society of Clinical Oncology (ASCO) 2007 annual meeting. The study included intravenous administration of higher doses than had been tested in previous studies.

"We found that atacicept was well-tolerated and biologically active at all dose levels in this study, consistent with the results of our other clinical trials," said Douglas E. Williams, Ph.D., Executive Vice President and Chief Scientific Officer of ZymoGenetics. "Together with our partner Merck Serono, we will assess the results of this and our other B-cell malignancy studies, once the studies are complete, to see whether the data support moving forward in these indications."

Atacicept in B-CLL Study Design and Results

In a Phase 1b open-label, dose escalation study, 15 patients with refractory or relapsed disease were given weekly intravenous doses of atacicept ranging from 1 mg/kg to 20 mg/kg, for five weeks. Treatment with atacicept was well tolerated at all dose levels in the study. No dose limiting toxicities or serious adverse events related to study drug have been reported to date. Among the six patients given 10 mg/kg and 15 mg/kg, three (50%) showed signs of disease stabilization, using National Cancer Institute-sponsored Working Group criteria, during the treatment period. Prior to atacicept treatment, all of these patients had rapidly increasing leukocyte counts. One patient, who received 10 mg/kg, exhibited stable disease for over six months.

Biological activity of atacicept was demonstrated in these patients by reduced immunoglobulin (Ig) concentrations after treatment at all dose levels. Mean IgA, IgG and IgM concentrations decreased by 20%, 22% and 15% from baseline, respectively, af
'"/>




Page: 1 2 3

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2020)... ... May 23, 2020 , ... Federal data has already ... African American. However, many news reports are failing to report that many of those ... denied a test multiple times. , A new song by an artist that calls ...
(Date:5/21/2020)... ... May 21, 2020 , ... ... in mid-March 2020 to deliver thousands of critical Personal Protection Equipment (PPE) devices ... their usual aerospace production work, the three companies teamed together to start production ...
(Date:5/21/2020)... PENNSAUKEN, N.J (PRWEB) , ... May 21, 2020 ... ... fully integrated aluminum services resource, donated its second COVID-19 drive-through testing shelter in ... partnership with the Camden County Freeholders and Connor Strong & Buckelew and is ...
Breaking Medicine Technology:
(Date:5/21/2020)... ... May 21, 2020 , ... Having ... of GSCG, VITA NOVAS has already gained ground with the inherited reputation of ... stimulating biological products intravenously, guaranteeing an effective way for the ingredients to become ...
(Date:5/21/2020)... , ... May 21, 2020 , ... Friends of Lisa ... has been endorsed by Planned Parenthood Southeast Advocates (PPSEA). PPSEA educates ... family planning and the full range of reproductive health care. PPSEA educates and lobbies ...
(Date:5/21/2020)... AUSTIN, Texas (PRWEB) , ... May 21, 2020 , ... ... fire departments and hospitals, today announced the findings of its 2020 ESO Fire ... the number of EMS calls versus fire-related calls, first apparatus turnout time and travel ...
(Date:5/21/2020)... ... May 21, 2020 , ... Casenet® LLC ... platform that supports care management and utilization management at health insurance plans. Developed ... TruCare 2020 provides significant usability and automation upgrades to all of its existing ...
(Date:5/21/2020)... ... May 21, 2020 , ... JNL Technologies Inc. ... announced the release of the SafeHealth screening software. This tool allows companies ... for additional staff or the cost of additional paperwork management. , SafeHealth allows you ...
Breaking Medicine News(10 mins):